Mainolfi Nello's Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Jul 7, 2026
- Accession no.
- 0001193125-26-297817
- Filed
- Jul 7, 2026, 8:00 PM ET
- Trade date
- Jul 7, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.95M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mainolfi NelloCIK 0001821189 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | MOption exerciseAcquired | +50,000 | $2.08 | +$104,000 | 716,568 | Direct | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −50,000 | $119.00 | −$5,950,000 | 666,568 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | MOption exerciseDisposed | −45,559 | $0.00 | $0 | 90,000 | Direct | |
| Jul 7, 2026 | Common Stock | MOption exerciseDisposed | −4,441 | $0.00 | $0 | 14,284 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.